MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing
- Mirus Bio’s transfection reagents strengthen MilliporeSigma’s upstream portfolio
- Acquisition will advance company’s ambition to provide a fully integrated and comprehensive solution for viral vector manufacturing
- Reinforces MilliporeSigma’s continued commitment to shaping the future of gene therapies and other novel modalities
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523946881/en/
“Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years1 and will continue to advance, with a projected growth of 30 percent until 20282,” said
“We have been driving innovation in nucleic acid delivery for two decades,” said
MilliporeSigma’s Process Solutions business offers one of the broadest product portfolios in the industry and provides flexible solutions for viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production. This comprehensive portfolio includes cell lines, cell culture media, processing chemicals and buffers, enzymes, as well as systems, filters, hardware and consumables to support every step of the viral vector manufacturing processes. Its expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, MilliporeSigma’s Life Science Services business offers both contract testing services and a suite of comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies to de-risk the path to commercialization.
This deal is anticipated to close in Q3 of 2024 and is subject to regulatory clearance and other customary closing conditions.
About the Life Science business of
The Life Science business of
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023,
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are
Follow
All
1
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
2 EvaluatePharma 2023
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523946881/en/
rachel.bloom-baglin@milliporesigma.com
978-436-1725
Source: